Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior PLC obtained strong shareholder approval for a scheme of arrangement and amended and restated articles of association that reshape its corporate structure. A new Article 136 ensures that any ordinary shares issued after the Amended Articles take effect but before the Scheme Record Time are automatically subject to the scheme, so all Indivior PLC shareholders will become shareholders of Indivior Pharmaceuticals, Inc. and Indivior PLC will become its wholly-owned subsidiary.
At a Court Meeting, 15 shareholders voted for the scheme and 2 against, with 94,968,161 votes for and 46,544 against, exceeding the English law requirement of a majority in number representing not less than seventy-five percent in value of shares present and voting. At an Extraordinary General Meeting, shareholders passed six related special resolutions, including authorising directors to implement the scheme, reducing share capital, issuing New Indivior Shares, amending articles, re-registering the company as a private company limited by shares, and adopting post-scheme articles. Completion of the scheme still depends on sanction by the High Court of Justice, with a hearing expected on January 22, 2026, and completion is expected later in January 2026.
Indivior PLC reported that it has fulfilled all remaining obligations under its Resolution Agreement with the U.S. Department of Justice and the U.S. Attorney’s Office for the Western District of Virginia. After these obligations were satisfied, the Resolution Agreement terminated on November 20, 2025. The company also issued a press release on the same date announcing payment of the remaining amounts owed to the DOJ, which is included as an exhibit to this report. This marks the formal conclusion of that material agreement with U.S. authorities.
Indivior PLC announced it has mailed and published a scheme circular for an Extraordinary General Meeting on December 11, 2025. Shareholders will vote on the proposed re‑domestication of the company from the U.K. to Delaware. The scheme circular is furnished as Exhibit 99.1.
Indivior PLC announced an enterprise-wide restructuring under its Indivior Action Agenda to simplify operations and focus on growth drivers. The company expects to realize at least $150 million in annual operating expense savings beginning in 2026 and to enter Phase II — Accelerate — with immediate accretion to the bottom line starting January 2026.
Actions include headcount reductions, R&D facility closures, discontinuing sales and marketing support for OPVEE, and optimizing the Rest of World footprint by exiting several non-U.S. markets while retaining Canada, Australia, France and sales in Germany, which represent 77% of forecasted ROW net revenue and 94% of forecasted ROW adjusted EBITDA. Indivior expects total pre-tax restructuring charges of approximately $105 to $130 million, including $73 to $92 million of cash costs. In Q3 2025, $65 million was recognized and adjusted from non-GAAP results. Itemized estimates include severance of $33 to $37 million, real estate of $15 to $21 million, asset impairments of $21 to $27 million, contract terminations of $25 to $28 million, and $11 to $17 million for consulting, legal, and tax planning.
Indivior PLC filed its Q3 2025 10-Q, reporting net revenue of $314 million (up from $307 million) and net income of $42 million (vs. $22 million). Diluted EPS was $0.33 (vs. $0.16). Gross margin was 73% (vs. 79%), reflecting Q3 charges tied to portfolio actions.
SUBLOCADE remained the growth driver with total net revenue of $219 million (U.S. $203 million), offsetting declines in sublingual products, OPVEE, and PERSERIS. For the first nine months, net revenue was $881 million (vs. $889 million) with net income of $108 million (vs. a $14 million loss).
The company recorded $72 million in Q3 costs, including $35 million for Phase 1 of the Indivior Action Agenda and $37 million related to discontinuing sales and marketing support for OPVEE. Cash and equivalents were $445 million and debt totaled $322 million (current $18 million, long‑term $304 million). Operating cash flow for the first nine months was $194 million. The company plans to exit several non‑U.S. markets, with expected charges of $30–$50 million, primarily in Q4 2025 and Q1 2026. Accrued litigation settlement expenses were $406 million, including an opioid-related settlement accrual of $80 million.
Indivior PLC furnished materials related to its latest results. The company issued a press release reporting financial results for the period ended September 30, 2025 and made accompanying presentation materials available on its website.
The press release was furnished as Exhibit 99.1, presentation materials as Exhibit 99.2, and an updated corporate presentation as Exhibit 99.3. The filing is signed by Chief Financial Officer Ryan Preblick.
Indivior PLC filed a report describing a press release issued on October 1, 2025 announcing its intent to redomicile from England and Wales to Delaware. The company explains that completing this move would require court approval in the U.K. and approval from its shareholders, and notes that timing, execution of its cost and capital reduction initiatives, and actions of third parties could all affect the outcome. Indivior characterizes these statements about redomiciling, potential timing, and potential benefits as forward-looking and highlights that actual results could differ materially due to various risks and uncertainties described in its recent Annual Report and Quarterly Reports filed with the SEC.
Form 144 notice for Indivior PLC (INDV): The filer notifies a proposed sale of 26,463 shares of Class A common stock through Merrill Lynch on 09/08/2025 with an aggregate market value of $655,000. The filing lists prior acquisitions of the shares: 13,805 shares bought on 03/26/2015 and 12,658 shares on 08/06/2019, both acquired on the open market for cash. The form also discloses sales by the same person within the past three months: 52,320 shares sold on 08/28/2025 for $1,278,178 and 30,000 shares sold on 09/04/2025 for $744,009.60. The filer certifies no undisclosed material adverse information and includes the required signature attestation.
Indivior PLC insider Mark Crossley filed a Form 144 notifying the proposed sale of 183,938 Class A common shares through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $4,593,150.74 and an approximate sale date of 09/08/2025. The securities were acquired on 03/09/2025 upon vesting of restricted stock units from Indivior PLC (243,282 units). The filing also discloses two recent sales by the same individual: 52,320 shares sold on 08/28/2025 for $1,278,178 and 30,000 shares sold on 09/04/2025 for $744,009.60. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Two Seas Capital (and related persons) reported beneficial ownership of 10,329,152 Ordinary Shares of Indivior plc, representing approximately 8.3% of the company's outstanding shares. These shares are held directly by two funds (the "Litigation Fund" and the "Global Fund") and TSC has sole voting and investment power over the securities pursuant to Investment Management Agreements. Aggregate purchase prices disclosed are approximately $38,987,296 for 6,311,887 shares held by the Litigation Fund and $45,107,871 for 4,017,265 shares held by the Global Fund. The Litigation Fund purchases were financed in part by a Credit Facility provided by UBS AG, London Branch. The filing also notes the Global Fund no longer holds any cash-settled swap positions.
Two Seas Capital (and related persons) reported beneficial ownership of 10,329,152 Ordinary Shares of Indivior plc, representing approximately 8.3% of the company's outstanding shares. These shares are held directly by two funds (the "Litigation Fund" and the "Global Fund") and TSC has sole voting and investment power over the securities pursuant to Investment Management Agreements. Aggregate purchase prices disclosed are approximately $38,987,296 for 6,311,887 shares held by the Litigation Fund and $45,107,871 for 4,017,265 shares held by the Global Fund. The Litigation Fund purchases were financed in part by a Credit Facility provided by UBS AG, London Branch. The filing also notes the Global Fund no longer holds any cash-settled swap positions.
Two Seas Capital (and related persons) reported beneficial ownership of 10,329,152 Ordinary Shares of Indivior plc, representing approximately 8.3% of the company's outstanding shares. These shares are held directly by two funds (the "Litigation Fund" and the "Global Fund") and TSC has sole voting and investment power over the securities pursuant to Investment Management Agreements. Aggregate purchase prices disclosed are approximately $38,987,296 for 6,311,887 shares held by the Litigation Fund and $45,107,871 for 4,017,265 shares held by the Global Fund. The Litigation Fund purchases were financed in part by a Credit Facility provided by UBS AG, London Branch. The filing also notes the Global Fund no longer holds any cash-settled swap positions.